Literature DB >> 17160024

Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3.

M Graessmann1, B Berg, B Fuchs, A Klein, A Graessmann.   

Abstract

Impairment of the complex regulatory network of cell death and survival is frequently the reason for therapy resistance of breast cancer cells and a major cause of tumor progression. We established two independent cell lines from a fast growing mouse breast tumor (WAP-SVT/t transgenic animal). Cells from one line (ME-A cells) are sensitive to apoptotic stimuli such as growth factor depletion or treatment with antitumor agents (e.g. doxorubicin). Cells from the second line (ME-C cells), which carry a missense mutation at the p53 codon 242, are very insensitive to apoptotic stimuli. Co-cultivation experiments revealed that the ME-C cells mediate cell death resistance to the ME-A cells. Microarray and Western blot analysis showed that osteopontin (OPN) is selectively overexpressed by the ME-C cells. This glycoprotein is the most abundant protein secreted by the ME-C cells and we obtained strong indications that OPN is the main antiapoptotic factor. However, the OPN containing ME-C cell medium does not alter the expression level of pro- or antiapoptotic genes or known inhibitors of apoptosis (IAPs). Its signaling involves mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)1/2 as the kinase inhibitor PD98059 restores apoptosis but not the Akt inhibitor. In the ME-A cells, mitochondrial cytochrome c release occurs with and without external apoptotic stimuli. OPN containing ME-C cell medium does not prevent the mitochondrial cytochrome c release and caspase-9 processing. In serum starved ME-A cells, the OPN containing ME-C cell medium prevents caspase-3 activation. However, in doxorubicin-treated cells, although apoptosis is blocked, it does not inhibit caspase-3. This indicates that the ME-A cells distinguish between the initial apoptotic stimuli and that the cells possess a further uncharacterized control element acting downstream from caspase-3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160024     DOI: 10.1038/sj.onc.1210096

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.

Authors:  Holger G Hass; Oliver Nehls; Juergen Jobst; Andrea Frilling; Ulrich Vogel; Stephan Kaiser
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

2.  Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression.

Authors:  Ramesh Butti; Ramakrishna Nimma; Gautam Kundu; Anuradha Bulbule; Totakura V S Kumar; Vinoth Prasanna Gunasekaran; Deepti Tomar; Dhiraj Kumar; Anupama Mane; Satyajit S Gill; Tushar Patil; Georg F Weber; Gopal C Kundu
Journal:  Oncogene       Date:  2021-02-18       Impact factor: 9.867

Review 3.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

4.  Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.

Authors:  K D M Nakamura; T M Tilli; J L Wanderley; A Palumbo; R M Mattos; A C Ferreira; C E Klumb; L E Nasciutti; E R Gimba
Journal:  Tumour Biol       Date:  2015-09-24

5.  Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.

Authors:  Benjamin Gottschalk; Andreas Klein
Journal:  Mol Cell Biochem       Date:  2013-04-07       Impact factor: 3.396

6.  Osteopontin expression in normal skin and non-melanoma skin tumors.

Authors:  Pi-Ling Chang; Louie Harkins; Yu-Hua Hsieh; Patricia Hicks; Kraisorn Sappayatosok; Somchai Yodsanga; Somporn Swasdison; Ann F Chambers; Craig A Elmets; Kang-Jey Ho
Journal:  J Histochem Cytochem       Date:  2007-10-15       Impact factor: 2.479

7.  Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer.

Authors:  Jung Hye Choi; Jim Jinn-Chyuan Sheu; Bin Guan; Natini Jinawath; Paul Markowski; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

8.  Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer.

Authors:  Lui Ng; Timothy Wan; Ariel Chow; Deepak Iyer; Johnny Man; Guanghua Chen; Thomas Chung-Cheung Yau; Oswens Lo; Chi-Chung Foo; Jensen Tung-Chung Poon; Ronnie Tung-Ping Poon; Roberta Pang; Wai-Lun Law
Journal:  Stem Cells Int       Date:  2015-05-27       Impact factor: 5.443

9.  Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression.

Authors:  Yanhua Wu; Wenjun Jiang; Yingming Wang; Jun Wu; Hexige Saiyin; Xiaojing Qiao; Xinyu Mei; Bin Guo; Xiao Fang; Lu Zhang; Huiling Lou; Chaoqun Wu; Shouyi Qiao
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

10.  Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors.

Authors:  Kai-Hsi Hsu; Hung-Wen Tsai; Pin-Wen Lin; Yun-Shang Hsu; Pei-Jung Lu; Yan-Shen Shan
Journal:  World J Surg Oncol       Date:  2014-06-20       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.